Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDPK1 | O15530 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CNR1 | P21554 | 1/20 | 0.49 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | PLAAT3 | P53816 | 1/20 | 0.46 |
| ▸ | PLAAT5 | Q96KN8 | 1/20 | 0.46 |
| ▸ | PLAAT2 | Q9NWW9 | 1/20 | 0.46 |
| ▸ | PLAAT4 | Q9UL19 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ACLY | P53396 | 2/20 | 0.45 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30799277 | 1.00 | PDPK1 (0.54) | PDPK1GAACNR1IDO1HPGD | |
| SCHEMBL1923067 | 0.91 | ACLY (0.50) | PDPK1GAACNR1IDO1HPGD | |
| SCHEMBL11637870 | 0.86 | ACLY (0.56) | ACLY | |
| SCHEMBL7330078 | 0.85 | PDPK1 (0.56) | PDPK1CNR1IDO1HPGDPLAAT3 | |
| SCHEMBL586345 | 0.83 | PDPK1 (0.59) | PDPK1CNR1HPGDPLAAT3PLAAT5 | |
| SCHEMBL2489075 | 0.83 | PDPK1 (0.55) | PDPK1CNR1IDO1HPGDPLAAT3 | |
| SCHEMBL30567601 | 0.83 | PDPK1 (0.59) | PDPK1CNR1HPGDPLAAT3PLAAT5 | |
| SCHEMBL22123457 | 0.82 | PYCR1 (0.42) | PDPK1GAAIDO1CYP1A2CYP2C9 | |
| SCHEMBL29159434 | 0.82 | PDPK1 (0.51) | PDPK1CNR1IDO1HPGDPLAAT3 | |
| SCHEMBL2625213 | 0.82 | PDPK1 (0.51) | PDPK1GAACNR1IDO1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117603029-A | Synthesis method of penconazole key intermediate | 江苏禾本生化有限公司 | 2024-02-27 | — | — | CN | claimed |
| CN-102584726-B | Method for preparing penconazole serving as bacteriacide | ZHEJIANG HEBEN PESTICIDE & CHEMICALS CO LTD | 2014-05-14 | — | — | CN | claimed |
| CN-103304394-A | Synthetic method of 2,4-dichlorobenzene butanone | JIANGYAN KEYAN FINE CHEMICAL CO LTD | 2013-09-18 | — | — | CN | claimed |
| US-7470701-B2 | Substituted 2,5-heterocyclic derivatives | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-12-30 | — | — | US | claimed |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2008-10-16 | — | — | US | claimed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | claimed |
| CN-117603029-A | Synthesis method of penconazole key intermediate | 江苏禾本生化有限公司 | 2024-02-27 | — | — | CN | disclosed |
| EP-3082420-B1 | SYNERGISTIC HERBICIDAL WEED CONTROL AND IMPROVED CROP TOLERANCE FROM COMBINATIONS OF 2,4-D-CHOLINE, GLYPHOSATE, AND GLUFOSINATE IN 2,4-D-, GLYPHOSATE- AND GLUFOSINATE-TOLERANT SOYBEANS, CORN, COTTON AND OTHER CROP AREAS | DOW AGROSCIENCES LLC (US) | 2020-10-28 | — | — | EP | disclosed |
| CN-102584726-B | Method for preparing penconazole serving as bacteriacide | ZHEJIANG HEBEN PESTICIDE & CHEMICALS CO LTD | 2014-05-14 | — | — | CN | disclosed |
| CN-103304394-A | Synthetic method of 2,4-dichlorobenzene butanone | JIANGYAN KEYAN FINE CHEMICAL CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-103304394-A | Synthetic method of 2,4-dichlorobenzene butanone | JIANGYAN KEYAN FINE CHEMICAL CO LTD | 2013-09-18 | — | — | CN | disclosed |
| CN-103304394-A | Synthetic method of 2,4-dichlorobenzene butanone | JIANGYAN KEYAN FINE CHEMICAL CO LTD | 2013-09-18 | — | — | CN | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| WO-2005111008-A2 | COMPOUNDS FOR ENZYME INHIBITION | PROTEOLIX, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | CHIRON CORPORATION (US) | 2005-11-17 | — | — | US | disclosed |
| EP-1317433-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2003-06-11 | — | — | EP | disclosed |
| WO-2002020495-A2 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 2002-03-14 | — | — | WO | disclosed |
| EP-1087963-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | Chiron Corporation (US) | 2001-04-04 | — | — | EP | disclosed |
| WO-1999065897-A1 | INHIBITORS OF GLYCOGEN SYNTHASE KINASE 3 | CHIRON CORPORATION (US) | 1999-12-23 | — | — | WO | disclosed |
| EP-0117578-A2 | Azole-substituted alcohol derivatives | SHIONOGI & CO., LTD. (JP) | 1984-09-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256121-A1 | e.g. 3-(4-fluorophenyl)-N-{5-[2-(methylamino)pyrimidin-4-yl]thien-2-yl}propanamide; PKB/Akt kinase inhibitor; anticarcinogenic agent; carcinoma, cancer metastases, squamous cell carcinoma, esophageal squamous cell carcinoma, oral carcinoma, cutaneous T cell lymphoma, Hodgkin's lymphoma | MALT1, AKT1, PIK3CA | PDPK1 22/4885GAA 1540/4885CNR1 4211/4885 |
| US-20080255120-A1 | SUBSTITUTED 2,5-HETEROCYCLIC DERIVATIVES | CYP3A5, ABCG2, ABCB1 | PDPK1 4290/4885GAA 227/4885CNR1 320/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PDPK1 3894/4885GAA 136/4885CNR1 4218/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.